Apitegromab is now an approved medicine, but only for one disease. On September 11, 2026, the Food and Drug Administration approved it under the brand name Isembyld for spinal muscular atrophy (SMA), a rare inherited condition in which the nerve cells that control muscles are gradually lost. It is not approved for obesity, and it is not approved to protect muscle during weight loss on a GLP-1 medication.

So why is a rare-disease drug in weight-loss headlines? The same antibody was tested alongside tirzepatide in a small trial, and people who got both lost less lean tissue. That trial is worth understanding, and it is a long way from a treatment anyone is prescribed for that purpose.

What the apitegromab approval covers

As of September 22, 2026, the day this article was written, FDA's list of novel drug approvals for 2026 shows Isembyld (apitegromab-mstn) approved on September 11 "to treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment."

That last clause matters: Isembyld is added on top of an existing SMA drug such as nusinersen or risdiplam, which help motor nerves survive, rather than replacing it.

The prescribing information on DailyMed, which carries the line "Revised: 9/2026", describes a monoclonal antibody (a lab-made immune protein built to latch onto one target) given as an IV infusion every four weeks, with the dose set by body weight. FDA's approval announcement calls it "the first therapy approved for SMA that directly targets muscle loss."

Why people on a GLP-1 are paying attention

When weight comes off on semaglutide or tirzepatide, not all of it is fat. Some is lean mass: everything that isn't fat or bone, which includes muscle but also water, organs and connective tissue. The researchers behind the tirzepatide trial described below put the lean share of weight lost on these drugs at roughly a quarter to two-fifths.

Our pages on muscle loss with semaglutide and exercise on tirzepatide cover what the body scans measured and why lean mass is not the same thing as muscle. The question for drug developers is narrower: could blocking one muscle signal tip that split toward fat?

How it works: switching off a brake on muscle

Myostatin is a protein made mainly in muscle that acts as a brake on muscle growth. Drug developers have tried to block it for decades, mostly without clinical success. According to the label, apitegromab binds myostatin's inactive precursor forms and stops them from being switched on.

The approval rests on a trial called SAPPHIRE, which enrolled 188 children and young adults aged 2 to 21 who could not walk and were already on nusinersen or risdiplam (Crawford et al., Lancet Neurology 2025). On a 66-point scale of motor skills such as sitting and standing, children 2 to 12 on the approved dose finished about 2.2 points ahead of placebo after a year, according to the label: their scores rose 1.0 point while the placebo group's fell 1.2.

The label carries one warning, and it is about bones. In that trial, 5 of 53 children on the approved dose (9%) had a fracture, compared with 1 patient on placebo (2%), and rat studies showed bone damage. In a September 15 filing, Scholar Rock said FDA asked it to send in every fracture case as a 15-day alert report and required a pregnancy safety study.

What the apitegromab and tirzepatide trial found

The trial is called EMBRAZE. It enrolled 102 adults with overweight or obesity at seven U.S. sites, aged 18 to 65 and without diabetes; about four in five were women (Pratley et al., Nature Medicine 2026). Everyone got tirzepatide, stepped up toward 15 mg a week following the approved label. Half also got apitegromab infusions every four weeks; half got placebo. The main measure was lean mass after 24 weeks on a DXA scan, a low-dose X-ray that sorts the body into fat, bone and lean tissue.

Among the 87 people who finished and had a final scan, those on apitegromab lost 1.6 kg of lean mass (about 3.5 pounds), against 3.5 kg (about 7.7 pounds) with placebo. Total weight loss was similar: 11.2 kg versus 12.5 kg. Lean tissue made up about 15% of the weight lost with apitegromab and about 30% with placebo.

Three limits matter as much as that headline:

  • It measured tissue, not strength. A handheld muscle-force test and a chair sit-to-stand test were exploratory measures, and the paper reports no notable difference between the groups.
  • It used a looser statistical bar. The authors set significance at 20% rather than the usual 5%, which suits an early proof-of-concept study but is not a final answer.
  • It was short and narrow. Twenty-four weeks, mostly women, nobody with diabetes, and bone health was not among its stated endpoints.

Side effects were broadly similar, though fatigue was more common with apitegromab added (25% versus 12%). One person in each group had a serious adverse event.

The semaglutide combination Lilly tested

A second antibody, bimagrumab, works one step further along: it blocks the receptors that myostatin and a related signal, activin A, act through. It is still investigational. Lilly's phase 2 BELIEVE trial gave 507 adults with obesity semaglutide, bimagrumab, both, or placebo for 48 weeks (Heymsfield et al., Nature Medicine 2026).

On the highest-dose combination, people lost 17.8 kg (about 39 pounds) on average, against 14.2 kg (about 31 pounds) on semaglutide 2.4 mg alone. Lean mass fell 1.3 kg on that combination and 3.9 kg on semaglutide alone. The trade-off was tolerability: 14% to 21% of people on bimagrumab alone stopped treatment because of side effects, against 4% to 9% on semaglutide alone.

What the approval does not mean

Some coverage has framed apitegromab as an obesity drug that saves muscle. The label and FDA's listing say SMA, and nothing else.

  • It is not a GLP-1 add-on. The approval covers people with SMA who are already on an SMN2-targeted drug. Nothing here suggests using it any other way.
  • The muscle question is not settled. EMBRAZE showed less lean tissue lost on a scan over 24 weeks. It did not show better strength, better function, fewer falls or long-term safety in adults losing weight.
  • The SMA data do not transfer. SAPPHIRE studied children and young adults with a nerve disease, and the label notes that no one 65 or older was included. Whether the fracture signal applies to adults with obesity is unknown.

What to watch next

As of September 22, 2026, the day this article was written, Scholar Rock's quarterly report, filed August 6, 2026, says the company is focusing on rare neuromuscular diseases and is "seeking partners to further evaluate the potential for myostatin inhibition in combination with GLP-1 weight loss approaches" (Form 10-Q).

Lilly's phase 2 trial of bimagrumab with tirzepatide, which enrolled 252 adults without type 2 diabetes, lists a primary completion date of January 2026 and had no posted results on its ClinicalTrials.gov record. Its results would be the next real data point for people on tirzepatide.

What people on a GLP-1 can discuss today

Neither antibody is part of GLP-1 care today: bimagrumab is investigational, and apitegromab's only approved use is SMA. What a provider can weigh now is the ordinary toolkit: enough protein, resistance exercise, a dose pace that still lets someone eat well, and how strength and daily function are holding up. For semaglutide, exercise on semaglutide covers what the trials show about staying active.

Through Promise, tirzepatide and semaglutide are dispensed as compounded medications, which is different from an FDA-approved product: the formulations offered here are not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor. A licensed provider reviews every request, and not everyone qualifies. How tirzepatide gets prescribed walks through that review.